Kidney blood-vessel cell damage from fats in Alport syndrome

Glomerular endothelial damage: a new role of the lipids in Alport syndrome

NIH-funded research Children's Hospital of Los Angeles · NIH-11237997

This project looks at whether abnormal fat handling in tiny kidney blood vessels helps cause damage in people with Alport syndrome.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionChildren's Hospital of Los Angeles NIH-funded
Lab location1 site (Los Angeles, United States)
Project IDNIH-11237997 on NIH RePORTER

What this research studies

Researchers are focusing on the cells that line the tiny blood vessels in the kidney (glomerular endothelial cells) to understand early changes in Alport syndrome. They use a mouse model of Alport disease plus lab tests that measure gene activity, lipid content, and advanced imaging to find metabolic changes before major kidney cell loss. The team is studying signaling pathways such as VEGF and PI3K/Akt/mTOR that may drive the lipid changes and endothelial dysfunction. They are also testing whether extracellular vesicles from amniotic fluid stem cells can protect these kidney cells in their models, which could point toward new treatments.

Who could benefit from this research

Good fit: People with a diagnosis of Alport syndrome, especially those with early-stage kidney involvement, would be the most relevant candidates for related future studies or sample donation.

Not a fit: People without Alport syndrome or those with kidney failure from unrelated causes are unlikely to benefit directly from this specific line of research.

Why it matters

Potential benefit: If successful, this work could point to new therapies that protect kidney blood-vessel cells by correcting abnormal lipid metabolism or using protective extracellular vesicles.

How similar studies have performed: Previous laboratory and animal work has linked lipid changes and VEGF/PI3K signaling to kidney injury and has shown promise for extracellular vesicle approaches, but focusing on glomerular endothelial lipid metabolism is a newer angle.

Where this research is happening

Los Angeles, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alport syndromeAlport syndrome (AS, ATS)Alport syndrome-like hereditary nephritisAlport syndrome-like hereditary nephritis (ASLHN, ASLN)Alport's Syndrome
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.